Skip to main content
SpringerLink
Log in

Medical Treatment: Neuroprotection

  • Chapter
  • First Online:
Pearls of Glaucoma Management

Abstract

Apoptosis is the predominant cause of retinal ganglion cell (RGC) loss in glaucoma. While there is biological plausibility and experimental evidence for neuroprotection with various drugs, definitive clinical evidence for it still is lacking.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Glaucoma Panel. Primary open angle glaucoma preferred practice pattern guidelines. San Francisco: American Academy of Ophthalmology; 2013.

    Google Scholar 

  2. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711–20.

    Article  PubMed  Google Scholar 

  3. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–11.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–13; discussion 829–30.

    Article  PubMed  Google Scholar 

  5. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126(4):487–97.

    Article  Google Scholar 

  6. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429–40.

    Article  Google Scholar 

  7. Yang H, He L, Gardiner SK, Reynaud J, Williams G, Hardin C, Strouthidis NG, Downs JC, Fortune B, Burgoyne CF. Age-related differences in longitudinal structural change by spectral-domain optical coherence tomography in early experimental glaucoma. Invest Ophthalmol Vis Sci. 2014;55(10):6409–20.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gryta R, Sigal IA, Ruberti JW, Meschke G, Downs JC. Lamina cribrosa thickening in early glaucoma predicted by a microstructure motivated growth and remodeling approach. Mech Mater. 2012;44:99–109.

    Article  Google Scholar 

  9. Lee EJ, Kim TW, Weinreb RN, Kim H. Reversal of lamina cribrosa displacement after intraocular pressure reduction in open-angle glaucoma. Ophthalmology. 2013;120(3):553–9.

    Article  PubMed  Google Scholar 

  10. Lee EJ, Kim TW, Kim M, et al. Recent structural alteration of the peripheral lamina cribrosa near the location of disc hemorrhage in glaucoma. Invest Ophthalmol Vis Sci. 2014;55(4):2805–15.

    Article  PubMed  Google Scholar 

  11. Quigley HA, Anderson DR. Distribution of axonal transport blockade by acute intraocular pressure elevation in the primate optic nerve head. Invest Ophthalmol Vis Sci. 1977;16(7):640–4.

    CAS  PubMed  Google Scholar 

  12. Quigley HA, McKinnon SJ, Zack DJ, et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci. 2000;41(11):3460–6.

    CAS  PubMed  Google Scholar 

  13. Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia. 2000;32(1):42–50.

    Article  CAS  PubMed  Google Scholar 

  14. Tezel G, Wax MB. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci. 2000;20(23):8693–700.

    CAS  PubMed  Google Scholar 

  15. Wang HG, Pathan N, Ethell IM, et al. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999;284(5412):339–43.

    Article  CAS  PubMed  Google Scholar 

  16. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006;5(2):160–70.

    Article  CAS  PubMed  Google Scholar 

  17. Wamsley S, Gabelt BT, Dahl DB, et al. Vitreous glutamate concentration and axon loss in monkeys with experimental glaucoma. Arch Ophthalmol. 2005;123(1):64–70.

    Article  CAS  PubMed  Google Scholar 

  18. Gupta N, Yucel YH. Glaucoma as a neurodegenerative disease. Curr Opin Ophthalmol. 2007;18(2):110–4.

    Article  PubMed  Google Scholar 

  19. Ju WK, Kim KY, Lindsey JD, et al. Intraocular pressure elevation induces mitochondrial fission and triggers OPA1 release in glaucomatous optic nerve. Invest Ophthalmol Vis Sci. 2008;49(11):4903–11.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kim SY, Shim MS, Kim KY, et al. Inhibition of cyclophilin D by cyclosporine A promotes retinal ganglion cell survival by preventing mitochondrial alteration in ischemic injury. Cell Death Dis. 2014;5:e1105 [PMCID: PMC3973219].

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lipton SA. The role of glutamate in neurodegenerative diseases including glaucoma. In: Weinreb RN, editor. Glaucoma neuroprotection. The Netherlands: Wolters Kluwer Health; 2006. p. 9–22.

    Google Scholar 

  22. Yucel YH, Gupta N, Zhang Q, et al. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol. 2006;124(2):217–25.

    Article  CAS  PubMed  Google Scholar 

  23. Memantine Update. www.glaucoma.org/treating/memantine_updat_1.php. Accessed at 21 Mar 2008.

  24. Gao H, Qiao X, Cantor LB, WuDunn D. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol. 2002;120(6):797–803.

    Article  CAS  PubMed  Google Scholar 

  25. Tatton WG, Chalmers-Redman RM, Tatton NA. Apoptosis and anti-apoptosis signalling in glaucomatous retinopathy. Eur J Ophthalmol. 2001;11 Suppl 2:S12–22.

    PubMed  Google Scholar 

  26. Wheeler LA, Woldemussie E, Lai RK. Alpha-2 agonists and neuronal survival in glaucoma. In: Weinreb RN, editor. Glaucoma neuroprotection. The Netherlands: Wolters Kluwer Health; 2005. p. 53–63.

    Google Scholar 

  27. Lindsey JD, Duong-Polk KX, Hammond D, Chindasub P, Leung CK, Weinreb RN. Differential protection of injured retinal ganglion cell dendrites by brimonidine. Invest Ophthalmol Vis Sci. 2015;56(3):1789–804.

    Article  CAS  PubMed  Google Scholar 

  28. Kent AR, Nussdorf JD, David R, et al. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology. 2001;108(4):784–7.

    Article  CAS  PubMed  Google Scholar 

  29. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S, Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;141(4):671–81.

    Article  Google Scholar 

  30. Zhang J, Wu SM, Gross RL. Effects of beta-adrenergic blockers on glutamate-induced calcium signals in adult mouse retinal ganglion cells. Brain Res. 2003;959(1):111–9.

    Article  CAS  PubMed  Google Scholar 

  31. Hollo G, Whitson JT, Faulkner R, et al. Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration. Invest Ophthalmol Vis Sci. 2006;47(1):235–40.

    Article  PubMed  Google Scholar 

  32. Netland PA, Chaturvedi N, Dreyer EB. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am J Ophthalmol. 1993;115(5):608–13.

    Article  CAS  PubMed  Google Scholar 

  33. Boehm AG, Breidenbach KA, Pillunat LE, et al. Visual function and perfusion of the optic nerve head after application of centrally acting calcium-channel blockers. Graefes Arch Clin Exp Ophthalmol. 2003;241(1):34–8.

    Article  CAS  PubMed  Google Scholar 

  34. Muskens RP, de Voogd S, Wolfs RC, et al. Systemic antihypertensive medication and incident open-angle glaucoma. Ophthalmology. 2007;114(12):2221–6.

    Article  PubMed  Google Scholar 

  35. Lee D, Shim MS, Kim KY, et al. Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma. Invest Ophthalmol Vis Sci. 2014;55(2):993–1005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Lindsey JD, Duong-Polk KX, Hammond D, et al. Protection of injured retinal ganglion cell dendrites and unfolded protein response resolution after long-term dietary resveratrol. Neurobiol Aging. 2015;36(5):1969–81.

    Article  CAS  PubMed  Google Scholar 

  37. Weinreb RN. Glaucoma neuroprotection: what is it? Why is it needed? Can J Ophthalmol. 2007;42(3):396–8.

    Article  PubMed  Google Scholar 

  38. Medeiros FA, Weinreb RN, Sample PA, et al. Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma. Arch Ophthalmol. 2005;123(10):1351–60.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shiley Eye Institute, Hamilton Glaucoma Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA

    Robert N. Weinreb M.D.

Authors
  1. Robert N. Weinreb M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert N. Weinreb M.D. .

Editor information

Editors and Affiliations

  1. David Geffen School of Medicine, University of California at Los Angeles, Veterans Health Administration of Greater Los Angeles, Jules Stein Eye Institute, David Geffen School of Medicine, University of California at Los Angeles, Veterans Health Administration of Greater Los Angeles, Los Angeles, California, USA

    JoAnn A. Giaconi

  2. David Geffen School of Medicine, University of California at Los Angeles, Jules Stein Eye Institute, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA

    Simon K. Law

  3. David Geffen School of Medicine, University of California at Los Angeles,, Jules Stein Eye Institute, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA

    Kouros Nouri-Mahdavi

  4. David Geffen School of Medicine, University of California at Los Angeles,, Jules Stein Eye Institute, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA

    Anne L. Coleman

  5. David Geffen School of Medicine, University of California at Los Angeles,, Jules Stein Eye Institute, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA

    Joseph Caprioli

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Weinreb, R.N. (2016). Medical Treatment: Neuroprotection. In: Giaconi, J., Law, S., Nouri-Mahdavi, K., Coleman, A., Caprioli, J. (eds) Pearls of Glaucoma Management. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49042-6_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-49042-6_28

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-49040-2

  • Online ISBN: 978-3-662-49042-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation